EHA 2020 – posters
June 15, 2020
Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients as well as several other posters during EHA.
See posters below.
Menu
-
Change Region
-
Global
-
United States
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you to the website of our US operations, Oncopeptides Inc. at oncopeptides-us.com
-
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Change Language
-
-
ONCO2.96 SEK+2.2%0.1 SEK
-
-
Change Region
-
Global
-
United States
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you to the website of our US operations, Oncopeptides Inc. at oncopeptides-us.com
-
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Change Language
-
-
ONCO2.96 SEK+2.2%0.1 SEK
-